Cambrex, a leading global contract development and manufacturing organization 
(CDMO) providing drug substance, drug product, and analytical services across 
the entire drug lifecycle, today announced that it has entered into a 
definitive agreement to acquire Snapdragon Chemistry, a leading US-based 
provider of chemical process development services to a broad range of emerging 
and established biopharma customers.

Snapdragon specializes in active pharmaceutical ingredient (API) batch and 
continuous flow process development, utilizing state-of-the-art automation 
technology and proprietary equipment to solve complex process and analytical 
development challenges. The team of scientists and engineers apply deep process 
understanding afforded by data-rich experimentation to design and rapidly 
execute efficient GMP and non-GMP manufacturing processes. With R&D and 
manufacturing headquartered in Waltham, Massachusetts, Snapdragon's 74 
employees come with strong ties to the local scientific community, with 31 PhD 
scientists on staff. 

"The acquisition of Snapdragon will accelerate our growth in the area of 
continuous flow process development and manufacturing, complementing our recent 
organic investments in our High Point, North Carolina facility," said Tom 
Loewald, CEO of Cambrex. "With R&D and manufacturing capabilities in the heart 
of Boston's biopharma hub, Snapdragon will continue to focus on solving their 
customers' most difficult process development challenges."

"We are excited to be joining Cambrex, a company with over 40 years of drug 
substance development and manufacturing expertise," said Matt Bio, CEO of 
Snapdragon. "Partnering our best-in-class process development capabilities with 
Cambrex's larger scale manufacturing facilities in North America and Europe is 
a natural fit, both for our employees and our customers."

Snapdragon recently opened its second facility, a new 51,000-square-foot 
facility to manufacture experimental pharmaceutical products for human clinical 
trials. The new facility expanded the company's capacity for supplying clinical 
intermediates and drug substances.

The transaction is expected to close following the completion of customary 
regulatory approvals.  This will be Cambrex's second acquisition within a year 
along with Q1 Scientific, consistent with its strategy to expand its portfolio 
of specialized solutions for pharmaceutical development and manufacturing.

About Cambrex

Cambrex is a leading global contract development and manufacturing organization 
(CDMO) that provides drug substance, drug product, and analytical services 
across the entire drug lifecycle. With over 40 years of experience and a 
growing team of over 2,300 experts servicing global clients from North America 
and Europe, Cambrex is a trusted partner in branded and generic markets for API 
and finished dosage form development and manufacturing.

Cambrex offers a range of specialized drug substance technologies and 
capabilities, including biocatalysis, continuous flow, controlled substances, 
solid-state science, material characterization, and highly potent APIs. In 
addition, Cambrex can support conventional dosage forms, including oral solids, 
semi-solids, and liquids, and has the expertise to manufacture specialty dosage 
forms such as modified-release, fixed-dose combination, pediatric, bi-layer 
tablets, stick packs, topicals, controlled substances, sterile, and non-sterile 
ointments.

Logo - https://mma.prnewswire.com/media/1198585/Cambrex_Logo.jpg

Source: Cambrex